Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

• मुख्य लेखकों: Kyung‐Sang Yu (लेखक), In‐Jin Jang (लेखक), Hyeong‐Seok Lim (लेखक), Jang Hee Hong (लेखक), Min‐Gul Kim (लेखक), Min Kyu Park (लेखक), Doo‐Yeoun Cho (लेखक), Min Soo Park (लेखक), Jae Yong Chung (लेखक), Jong‐Lyul Ghim (लेखक), SeungHwan Lee (लेखक), Seok Kyu Yoon (लेखक), In Sun Kwon (लेखक), Sang Joon Lee (लेखक), Sung Hyun Kim (लेखक), Yun Ju Bae (लेखक), Jung Bin Cha (लेखक), Daniel E. Furst (लेखक), Edward Keystone (लेखक), Jonathan Kay (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2021-07-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This double‐blind, parallel‐group, phase I trial (clini...